Nyhet

Inission: All-time-high sales inflated by Medtech - Nordea

Finwire / Börskollen

Publicerad: 27 Aug 2020 10:09 Uppdaterad: 28 Aug 2020 07:29

Inission reported all-time high sales in Q2, but still 8% below our estimate, as we had expected a bigger impact from the COVID-19-related orders communicated during the quarter. We expect these orders to continue contributing to sales in Q3. The EBIT margin was much stronger than expected at 6%, driven by reduced raw material costs due to a beneficial product mix. As a result of this, we raise 2020E-22E EBIT by 14-18%. During H2, we expect Norwegian production will contribute to an improved margin after completing the reorganisation at Lökken. We update our DCF-based fair value range to SEK 118-146 (116-134).

https://research.nordea.com/CompanyDetails/15054/Inission

Research feed

Börskollens app – Högt betyg ⭐⭐⭐⭐⭐ och 250.000 nedladdningar

Ladda hem

Vårt nyhetsbrev – Utvalda börsnyheter och heta investeringscase varje vecka

Prenumerera

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!